SYNthesis BioVentures

Investment thesis

Registered ESVCLP founded in 2022 (Parkville, Melbourne) investing in early-stage therapeutics — small molecules, biologics, and cell and gene therapies — for high-unmet-need indications. Aims to bridge continuity of capital from Australian academia through to venture financing and public markets. Led by Prof. Andrew Wilks and Amir Zalcenstein.

Notable portfolio

Sector focus